Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Alterity Therapeutics LimitedNASDAQ: ATHE

Revenue · Q2 FY2026 · quarter ended Dec 2025

Revenue remains negative

Q2 FY2026 revenue was A$0, compared with A$1.61M a year earlier. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of A$2.17M (-60.2%) for the fiscal year ending Jun 2026, a slowdown from the +35.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
A$5.44M+35.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+35.3%-60.2%-95.5 pp
3-year CAGR+2.0%-14.3%-16.3 pp
5-year CAGR+20.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

AUD · from the income statement

Latest · FY2025
5.44M AUD
Year-over-year change
+35.3%
4-year CAGR
+5.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +35.3% is the highest of 2, against a peer median of -11.0%.
  • Over three fiscal years its annual growth of +2.0% compares with a peer median of -25.1%.
ATHE Competitors
Revenue for ATHE and competitors
Company Period LTM YoY 3-year CAGR
ATHEAlterity Therapeutics LimitedFY2025A$5.44M AUD+35.3%+2.0%
DYAIDyadic International, Inc.LTM Mar 2026$2.97M USD-11.0%-25.1%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD——
Peer median (excluding ATHE) —-11.0%-25.1%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.